This inventor holds 6 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Solent Therapeutics, LLC. Active years: 2018-2026.
Company Filing History:
5 out of 1,222 
1 out of 1 Years Active: 2018-2026
Title: Steve Swann: Innovator in Pharmaceutical Compounds
Introduction
Steve Swann is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, holding a total of 6 patents. His work primarily focuses on developing compounds that address various medical conditions.
Latest Patents
Among his latest patents is a heterocyclic compound aimed at providing a solution for the prophylaxis or treatment of constipation. This invention presents a compound represented by a specific formula, which is detailed in the specification. Another significant patent involves 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives, which serve as inhibitors of MRGX2. This disclosure includes compounds of a defined formula, their tautomers, and pharmaceutically acceptable salts, along with methods for preparing these compounds and their applications in treating diseases associated with MRGX2.
Career Highlights
Steve has worked with prominent companies in the pharmaceutical industry, including Takeda Pharmaceutical Company Limited and Solent Therapeutics, LLC. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Steve has collaborated with notable professionals in his field, including Masaki Seto and Kazuaki Takami. These partnerships have further enhanced his research and development efforts.
Conclusion
Steve Swann's innovative work in pharmaceutical compounds demonstrates his commitment to improving medical treatments. His patents reflect a deep understanding of complex chemical structures and their potential applications in healthcare.